Audentes Therapeutics Company Profile (NASDAQ:BOLD)

About Audentes Therapeutics

Audentes Therapeutics logoAudentes Therapeutics, Inc. is an early-stage biotechnology company. The Company is focused on developing and commercializing gene therapy products for patients suffering from serious, life-threatening rare diseases caused by single gene defects. The Company has a portfolio of product candidates, including AT132 for the treatment of X-Linked Myotubular Myopathy (XLMTM); AT342 for the treatment of Crigler-Najjar Syndrome (Crigler-Najjar); AT982 for the treatment of Pompe disease, and AT307 for the treatment of the CASQ2 subtype of Catecholaminergic Polymorphic Ventricular Tachycardia (CASQ2-CPVT). The Company's subsidiary is Audentes Therapeutics UK Ltd. As of September 30, 2016, the Company had not generated any revenues.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: N/A
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: BOLD
  • CUSIP:
Key Metrics:
  • Previous Close: $15.80
  • 50 Day Moving Average: $16.33
  • 200 Day Moving Average: $16.49
  • 52-Week Range: $13.06 - $20.74
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -4.67
  • P/E Growth: -1.52
  • Market Cap: $349.77M
  • Outstanding Shares: 21,725,000
Profitability:
  • Return on Assets: -41.00%
Debt:
  • Debt-to-Equity Ratio: -0.03%
  • Current Ratio: 12.35%
  • Quick Ratio: 12.35%
Additional Links:
Companies Related to Audentes Therapeutics:

Analyst Ratings

Consensus Ratings for Audentes Therapeutics (NASDAQ:BOLD) (?)
Ratings Breakdown: 3 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $22.00 (36.14% upside)

Analysts' Ratings History for Audentes Therapeutics (NASDAQ:BOLD)
Show:
DateFirmActionRatingPrice TargetDetails
11/12/2016Piper Jaffray CompaniesSet Price TargetBuy$24.00View Rating Details
9/1/2016WedbushReiterated RatingOutperform$20.00View Rating Details
8/15/2016Cowen and CompanyInitiated CoverageOutperformView Rating Details
(Data available from 2/28/2015 forward)

Earnings

Earnings History for Audentes Therapeutics (NASDAQ:BOLD)
No earnings announcements for this company have been tracked by MarketBeat.com

Estimates

Earnings Estimates for Audentes Therapeutics (NASDAQ:BOLD)
Current Year EPS Consensus Estimate: $-4.11 EPS
Next Year EPS Consensus Estimate: $-3.46 EPS

Dividends

Dividend History for Audentes Therapeutics (NASDAQ:BOLD)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Audentes Therapeutics (NASDAQ:BOLD)
Institutional Ownership Percentage: 70.99%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
7/25/2016James E FlynnInsiderBuy400,000$15.00$6,000,000.00View SEC Filing  
7/25/2016Orbimed Advisors LlcDirectorBuy33,334$15.00$500,010.00View SEC Filing  
7/25/2016Versant Ventures Iv, LlcMajor ShareholderBuy35,000$15.00$525,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Audentes Therapeutics (NASDAQ:BOLD)
DateHeadline
us.rd.yahoo.com logoAudentes Therapeutics Announces FDA Clearance of Investigational New Drug Application for AT342 to Treat Crigler-Najjar Syndrome (NASDAQ:BOLD)
us.rd.yahoo.com - February 1 at 4:13 PM
us.rd.yahoo.com logo8:01 am Audentes Therapeutics announces that the FDA has cleared the investigational new drug (IND (NASDAQ:BOLD)
us.rd.yahoo.com - February 1 at 4:13 PM
streetinsider.com logoAudentes Therapeutics (BOLD) Receives FDA Clearance of IND Application for AT342 to Treat Crigler-Najjar Syndrome (NASDAQ:BOLD)
www.streetinsider.com - February 1 at 4:13 PM
News IconAudentes Therapeutics Inc BOLD Pharmaceuticals Healthcare Deals and Alliances Profile Prices from USD $250 (NASDAQ:BOLD)
www.bioportfolio.com - January 25 at 4:58 PM
finance.yahoo.com logoAudentes Therapeutics Provides Full Year 2017 Strategic Outlook and Financial Guidance (NASDAQ:BOLD)
finance.yahoo.com - January 9 at 5:03 PM
finance.yahoo.com logo8:04 am Audentes Therapeutics's cash position is projected to fund operations into late 2018; provides FY17 milestones (NASDAQ:BOLD)
finance.yahoo.com - January 9 at 5:03 PM
finance.yahoo.com logoAudentes Therapeutics to Present at the 35th Annual J.P. Morgan Healthcare Conference (NASDAQ:BOLD)
finance.yahoo.com - January 4 at 4:57 PM
4-traders.com logoAudentes Therapeutics : Appoints Julie Anne Smith to Board of Directors (NASDAQ:BOLD)
www.4-traders.com - December 14 at 4:35 PM
4-traders.com logoAUDENTES THERAPEUTICS, INC. : Change in Directors or Principal Officers (form 8-K) (NASDAQ:BOLD)
www.4-traders.com - December 13 at 4:40 PM
biz.yahoo.com logoAUDENTES THERAPEUTICS, INC. Files SEC form 8-K, Change in Directors or Principal Officers (NASDAQ:BOLD)
biz.yahoo.com - December 13 at 4:40 PM
insidermonkey.com logoHow Hedge Funds Played the Audentes Therapeutics Inc (BOLD) IPO (NASDAQ:BOLD)
www.insidermonkey.com - December 8 at 4:08 PM
4-traders.com logoAUDENTES THERAPEUTICS, INC. : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K) (NASDAQ:BOLD)
www.4-traders.com - November 30 at 5:43 AM
finance.yahoo.com logoAudentes Therapeutics Announces Initiation of Large-scale cGMP Production at its Gene Therapy Manufacturing Facility (NASDAQ:BOLD)
finance.yahoo.com - November 30 at 5:43 AM
finance.yahoo.com logoAudentes Therapeutics to Attend Piper Jaffray 28th Annual Healthcare Conference (NASDAQ:BOLD)
finance.yahoo.com - November 21 at 8:49 AM
fxpips.com logoThese Stocks are Making Gaps Up Before the Bell – WINS, NSPR, DGII, AYA, OBCI, EBIO, HAR (NASDAQ:BOLD)
www.fxpips.com - November 15 at 12:38 PM
marketexclusive.com logoAudentes Therapeutics, Inc. (NASDAQ:BOLD) Files An 8-K Reports Third Quarter 2016 Financial Results and Provides Corporate Update (NASDAQ:BOLD)
marketexclusive.com - November 14 at 3:28 PM
publicnow.com logoAudentes Therapeutics Reports Third Quarter 2016 Financial Results and Provides Corporate Update (NASDAQ:BOLD)
www.publicnow.com - November 10 at 12:19 PM
bizjournals.com logoSupersized IPO charges up med device maker's first day (NASDAQ:BOLD)
www.bizjournals.com - October 21 at 12:12 PM
biz.yahoo.com logoAUDENTES THERAPEUTICS, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits (NASDAQ:BOLD)
biz.yahoo.com - September 28 at 8:59 AM
publicnow.com logoAudentes Therapeutics to Present at Upcoming Investor Conferences (NASDAQ:BOLD)
www.publicnow.com - September 21 at 8:28 AM
biz.yahoo.com logoAUDENTES THERAPEUTICS, INC. Files SEC form 10-Q, Quarterly Report (NASDAQ:BOLD)
biz.yahoo.com - September 2 at 8:38 AM
News IconAudentes Therapeutics Reports Second Quarter 2016 Financial Results and (NASDAQ:BOLD)
www.biomedreports.com - September 1 at 12:23 PM
biz.yahoo.com logoAUDENTES THERAPEUTICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements a (NASDAQ:BOLD)
biz.yahoo.com - September 1 at 12:23 PM
publicnow.com logoAudentes Therapeutics Reports Second Quarter 2016 Financial Results and Provides Corporate Update (NASDAQ:BOLD)
www.publicnow.com - September 1 at 12:23 PM
bizjournals.com logoBay Area cosmetics company files for $100M IPO (NASDAQ:BOLD)
www.bizjournals.com - August 31 at 3:52 PM
wsj.com logo[$$] Biotech Investor Sofinnova Ventures Raises $595.5M Toward New Fund (NASDAQ:BOLD)
www.wsj.com - August 25 at 8:47 AM
streetinsider.com logoAudentes Therapeutics (BOLD) Enrolls First Patient in INCEPTUS Study of XLMTM (NASDAQ:BOLD)
www.streetinsider.com - August 18 at 12:20 PM
publicnow.com logoAudentes Therapeutics Announces First Patient Enrolled in the INCEPTUS Clinical Assessment Study of XLMTM (NASDAQ:BOLD)
www.publicnow.com - August 17 at 12:04 PM
finance.yahoo.com logoAudentes Therapeutics Initiated Overweight At Wedbush (NASDAQ:BOLD)
finance.yahoo.com - August 15 at 4:01 PM
finance.yahoo.com logoAudentes Therapeutics' Strong Pipeline Merits An Outperform Rating From Cowen And Company (NASDAQ:BOLD)
finance.yahoo.com - August 15 at 4:01 PM
finance.yahoo.com logoCoverage initiated on Audentes Therapeutics by Wedbush (NASDAQ:BOLD)
finance.yahoo.com - August 15 at 11:07 AM
publicnow.com logoAudentes Therapeutics Announces Pricing of Initial Public Offering (NASDAQ:BOLD)
www.publicnow.com - August 10 at 3:22 PM
finance.yahoo.com logoAudentes Therapeutics to Present at the 2016 Wedbush PacGrow Healthcare Conference (NASDAQ:BOLD)
finance.yahoo.com - August 8 at 8:43 AM
insidermonkey.com logoDeerfield Management Discloses Stake In Post-IPO Audentes Therapeutics (BOLD) (NASDAQ:BOLD)
www.insidermonkey.com - July 26 at 11:06 AM
247wallst.com logo4 IPOs on Calendar for Week of July 25 (NASDAQ:BOLD)
247wallst.com - July 24 at 10:55 AM

Social

What is Audentes Therapeutics' stock symbol?

Audentes Therapeutics trades on the NASDAQ under the ticker symbol "BOLD."

Where is Audentes Therapeutics' stock going? Where will Audentes Therapeutics' stock price be in 2017?

3 brokers have issued 1 year price targets for Audentes Therapeutics' shares. Their predictions range from $20.00 to $24.00. On average, they anticipate Audentes Therapeutics' share price to reach $22.00 in the next year.

When will Audentes Therapeutics announce their earnings?

Audentes Therapeutics is scheduled to release their next quarterly earnings announcement on Thursday, November, 10th 2016.

Who owns Audentes Therapeutics stock?

Audentes Therapeutics' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Orbimed Advisors LLC (22.10%), Deerfield Management Co. (6.46%), Franklin Resources Inc. (1.69%), FMR LLC (1.61%), Eventide Asset Management LLC (1.04%) and Alyeska Investment Group L.P. (0.46%). Company insiders that own Audentes Therapeutics stock include James E Flynn, Orbimed Advisors Llc and Versant Ventures Iv, Llc.

Who sold Audentes Therapeutics stock? Who is selling Audentes Therapeutics stock?

Audentes Therapeutics' stock was sold by a variety of institutional investors in the last quarter, including Alyeska Investment Group L.P..

Who bought Audentes Therapeutics stock? Who is buying Audentes Therapeutics stock?

Audentes Therapeutics' stock was purchased by a variety of institutional investors in the last quarter, including State Street Corp and Perceptive Advisors LLC. Company insiders that have bought Audentes Therapeutics stock in the last two years include James E Flynn, Orbimed Advisors Llc and Versant Ventures Iv, Llc.

How do I buy Audentes Therapeutics stock?

Shares of Audentes Therapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Audentes Therapeutics stock cost?

One share of Audentes Therapeutics stock can currently be purchased for approximately $16.16.

Audentes Therapeutics (NASDAQ:BOLD) Chart for Tuesday, February, 28, 2017


Institutional Ownership Chart

Institutional Ownership by Quarter for Audentes Therapeutics (NASDAQ:BOLD)

Earnings History Chart

Earnings by Quarter for Audentes Therapeutics (NASDAQ:BOLD)

Dividend History Chart

Dividend Payments by Quarter for Audentes Therapeutics (NASDAQ:BOLD)

Last Updated on 2/28/2017 by MarketBeat.com Staff